Valuation: NEOVACS SA

Market Cap 4.09K 4.77K 3.83K 3.5K 6.6K 457K 6.67K 45.26K 17.6K 229K 17.91K 17.53K 759K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -235K -188K -172K -324K -22.46M -328K -2.22M -865K -11.28M -881K -862K -37.31M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 114K
-0.74%+3.78%+3.74%+23.10% 51.61B
+1.01%-0.20%+471.68%+564.93% 44.89B
+0.16%+7.88%+36.14%+20.76% 42.77B
-0.66%+2.61%+18.59%+87.04% 42.58B
+0.88%-3.48%+17.20%+53.83% 31.82B
-0.12%+3.84%+33.73%+145.25% 17.33B
-0.53%+1.84% - - 16.63B
+0.58%+4.66%+7.17%+30.87% 14.76B
+1.15%+4.17%+84.49%+50.33% 14.09B
Average +0.19%+4.18%+84.09%+122.01% 30.72B
Weighted average by Cap. +0.10%+4.10%+100.58%+140.63%

Financials

2023 2024
Net sales 533K 622K 499K 456K 861K 59.6M 870K 5.9M 2.3M 29.93M 2.34M 2.29M 99.02M 434K 506K 406K 371K 700K 48.48M 708K 4.8M 1.87M 24.35M 1.9M 1.86M 80.55M
Net income -8.74M -10.2M -8.18M -7.48M -14.11M -977M -14.26M -96.79M -37.64M -491M -38.31M -37.48M -1.62B -32.91M -38.41M -30.79M -28.15M -53.12M -3.68B -53.69M -364M -142M -1.85B -144M -141M -6.11B
Net Debt -237K -276K -221K -202K -382K -26.42M -386K -2.62M -1.02M -13.27M -1.04M -1.01M -43.9M -205K -239K -192K -175K -331K -22.91M -335K -2.27M -883K -11.51M -899K -879K -38.07M
Logo NEOVACS SA
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-